

Cover Story
Conversation with The Cancer Letter
In an in-depth interview with The Cancer Letter, an FDA official clarified the agency's criteria for approval of drugs that target PD-1 and PD-L1.
Free
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- How City of Hope is turning microbiome science into better cancer care
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Charles Rudin named cancer center director at MSK
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - What are you reading in 2024?













